Insight Molecular Diagnostics Inc. (IMDX) Financial Ratio Screen
Follow screening changes
Email alerts are not currently available. Bookmark this page and check the financial period and retrieval date when reviewing a result.
MSCI new-inclusion financial-ratio snapshot
IMDX financial screening at a glance
Calculation date: 2026-10-17. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Diagnostics & Research) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style debt and cash reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 13.6% / 30% | 45.0% / 30% | 49.4% / 30% | N/A | RATIOS FAIL* |
| FTSE | 13.6% / 33% | 45.0% / 33% | 49.4% / 50% | N/A | RATIOS FAIL* |
Financial Highlights
Profitability
| Gross Margin | 48.7% | |
| Operating Margin | -3815.1% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -57.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | USD -22M |
| Free Cash Flow | USD -25M |
| Total Debt | USD 3M |
| Current Ratio | 2.0 |
| Total Assets | USD 26M |
Price & Trading
| Last Close | $2.79 |
| 50-Day MA | $3.97 |
| 200-Day MA | $4.99 |
| Avg Volume | 228K |
| Beta | 1.8 |
|
52-Week Range
$2.42
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-10-16 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is Insight Molecular Diagnostics Inc. (IMDX) halal to invest in?
The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is Insight Molecular Diagnostics Inc.'s debt ratio?
Insight Molecular Diagnostics Inc.'s debt ratio is 13.6% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are Insight Molecular Diagnostics Inc.'s key financial metrics?
Insight Molecular Diagnostics Inc. has a market capitalization of USD 100M in its listing currency, and revenue of USD 4M.
How often is the screening data updated?
Calculation date: 2026-10-17. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.